PMBS market cap only $733,152
wallstreetnewscast Newsletter
Wall Street Newscast Traders Newsletter ~~~~~~~~~~~~~~~~~~~~~~~~~~
~~~~~~~~~~~~~~~~~~~~~~~~~~
PMBS Issued Alert Based on Market Cap of $733,152 SCHOFIELD — PuraMed BioScience, Inc., (OTCBB: PMBS) a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that Ludlow Research re-issued its research opinion on the company based on low market capitalization valuation.
Report Highlights — Non-Prescription, All Natural Product to Treat Migraine Headaches — Clinical Trials Show the Product Outperforms #1 Prescription Competitor — Currently Available Nationwide at Walgreen`s and CVS/pharmacy stores — Launching Marketing and Distribution Campaign — Expanding Retail-Chain-Store Distribution — Holds Patent on Product — 38 Million Shares Outstanding — Market Cap under $1 Million Current ValuationAs of May 14, 2013, PuraMed BioScience had approximately 37.9 million common shares outstanding, thus giving the stock a market cap valuation of an estimated $733,152.
http://www.otcmarkets.com/stock/PMBS/company-info [http://r20.rs6.net/tn.jspe001qgwA21oW6s5avP6Sp8H4x2SzIhJ7gXpJEDCTLjPs1kYnVAnrHGZKgajbromgGP-5RW8aQcWZkrzZ4Q3b7OrlzGVi9xJ6RJ2S0kUdKc3a53-DvOuTXn68po_7SdiGVfS0S3oVHVnrwqgGHgpV6-hnTZ67Z4Ry5M7C] Recent Headlines May 21, 2013 LipiGesic=AE M Migraine Treatment Product Shown to be as Effective as Prescription Based Medications May 16, 2013 PuraMed BioScience=AE, Inc., Launches Its Business-to-Business Migraine First Aid Kit(TM) to Promote Workplace Health and Wellness May 13, 2013 PuraMed BioScience=AE Expands International Distribution with Order from Colombia, South America Apr 18, 2013 PuraMed BioScience=AE Inc., Announces Manufacturing and Packaging Vendors for LipiGesic=AE M, its Highly Effective, Non-Prescription Migraine Pain Reliever Apr 12, 2013 PuraMed BioScience to Expand Marketing of Over-the-Counter Migraine Product to Additional National Retail Cha About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic M, PuraMed BioScience plans to launch LipiGesic H for tension-type headaches and LipiGesic PM, which provides a remedy for insomnia and other sleep disorders. www.puramedbioscience.com ~~~~~~~~~~~~~~~~~~~~~~~~~~
About Wall Street Newscast Located in New York City, WallStreetNewscast.com (WSNC) has been providing Wall Street investor presentations for both public and private companies since 1998. WSNC offers a wide-range of services to companies and investor relation professionals to discuss their recent news announcements, earnings reports, and corporate events to a diverse network of individual and institutional investors on Wall Street.www.wallstreetnewscast.com [http://r20.rs6.net/tn.jspe001qgwA21oW6s4hU2Q16Rrc0AuNLkdHV_aX06RzeOw6lSri-PjUxXMf3t4mAcfdsaJSBbjb1R4rY4JV7iUlwoE1t7PTNoPkktQPaItGft8QXTx-N166Mdpgtc7Og1LO_zfN] Register online for our free traders newsletter at www.wallstreetnewscast.com/form/newsletter.html [http://r20.rs6.net/tn.jspe001qgwA21oW6s7Yb2qgGIisO5S_o5oYvT0Xamh0pN8nfj0z5k0XYoyChDtlk1be9BjVKuo3i_enAQoJ0OfxjHk83o1fV6T-hEJ8RogbposvtI1KBOOuzKXRp-pRDncXn0qgyJYEbCKAgeKoHmm_HIWNoBPW8a999ki3] ~~~~~~~~~~~~~~~~~~~~~~~~~~
~~~~~~~~~~~~~~~~~~~~~~~~~~
Safe Harbor Statements:
This investor presentation may include statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
Disclaimer:
This is NOT a solicitation to Buy or Sell any security, but rather is for informational purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Wall Street Newscast (“WSNC“) does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. WSNC, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encourage to consider this as a possible conflict of interest when reviewing this information. In Compliance with SEC Rule 17B Wall Street Newscast was compensated one thousand dollars for ongoing media coverage. WSNC may hold a position in above securities from time to time, and thus should be considered a possible conflict of interest when reviewing this report and information. These investments may involve a high degree of risk, thus investors are highly encouraged to consult with a financial advisor before any and all investments.
~~~~~~~~~~~~~~~~~~~~~~~~~~
Forward this email